Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes
Transfusion · 2024
DOI: 10.1111/trf.17706 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Transfusion, 2024. Verfasst von Allison Mo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Australia. Hauptthemen laut MEDLINE: Anemia, Myelodysplastic Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Newcastle Hospitals Charitable Funds, Charity at Leeds, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Anemia in myelodysplastic syndromes (MDS) is associated with poorer health‐related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2–4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low‐dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes. Study Design and Methods In this n‐of‐1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended‐matched RBCs are provided, with transfusion based upon the previous week's Hb/pre‐transfusion testing results to eliminate delays of awaiting contemporaneous cross‐matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences.
Results
The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter‐country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units.
Discussion
This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre‐transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Australia.
- Department of Haematology, Monash Health, Clayton, Australia.
- Austin Pathology & Department of Haematology, Austin Health, Heidelberg, Australia.
- Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
- Department of Haematology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
- Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
ORCID-Profile: Allison Mo, Le Thi Phung Thao, Zoe McQuilten
Förderung
- Newcastle Hospitals Charitable Funds
- Charity at Leeds
- National Health and Medical Research Council
- National Blood Authority
- Monash Haematology
- Australian and New Zealand Society of Blood Transfusion
Zitieren
APA
Mo, A., Wood, E., Shortt, J., Charlton, A., Evers, D., Hoeks, M., Pritchard, E., Daly, J., Hodgson, C., Opat, S., Bowen, D., Reynolds, J., Thi Phung Thao, L., Stanworth, S. J., & McQuilten, Z. (2024). Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes. Transfusion. https://doi.org/10.1111/trf.17706
Vancouver
Mo A, Wood E, Shortt J, Charlton A, Evers D, Hoeks M, et al. Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes. Transfusion. 2024. doi:10.1111/trf.17706
BibTeX
@article{Mo2024,
author = {Mo, Allison and Wood, Erica and Shortt, Jake and Charlton, Andrew and Evers, Dorothea and Hoeks, Marlijn and Pritchard, Elizabeth and Daly, James and Hodgson, Carol and Opat, Stephen and Bowen, David and Reynolds, John and Thi Phung Thao, Le and Stanworth, Simon J and McQuilten, Zoe},
title = {Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17706}
}
EUVIMED